ProCE Banner Activity

Adding Idecabtagene Vicleucel to the Treatment Armamentarium for Relapsed/Refractory Multiple Myeloma

Clinical Thought
The approval of the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel provides another treatment option for some patients with relapsed/refractory multiple myeloma. Review this expert commentary on how to incorporate this therapeutic agent into your practice.

Released: June 02, 2021

Expiration: June 01, 2022

Share

Faculty

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received funds for research support from Bluebird and consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Celgene, Immuneel, Karyopharm, and Takeda.